{
    "title": "114_hr639",
    "content": "The Act titled \"Improving Regulatory Transparency for New Medical Therapies Act\" amends the Federal Food, Drug, and Cosmetic Act to include scheduling of substances in new FDA-approved drugs. It specifies the effective date of drug approval and outlines the process for recommended controls under the CSA. The Secretary provides notice to the sponsor regarding issuing a scientific evaluation and recommending controls under the Controlled Substances Act. Approval of the application is delayed until the interim final rule controlling the drug is issued. The \"date of approval\" is defined as the later of the approval date of the application or the issuance date of the interim final rule. The Secretary notifies the sponsor about recommending controls under the Controlled Substances Act. Approval of the application is delayed until the interim final rule controlling the drug is issued. The \"date of approval\" is defined as the later of the approval date of the application or the issuance date of the interim final rule. Under the Controlled Substances Act, approval of an application is delayed until the interim final rule controlling the biological product is issued. The \"date of approval\" refers to the later of the application approval date or the issuance date of the interim final rule. Under the Controlled Substances Act, approval of an application is delayed until the interim final rule controlling the biological product is issued. The \"date of approval\" refers to the later of the application approval date or the issuance date of the interim final rule. In the case of recommended controls under the CSA, approval of the application is contingent on a scientific and medical evaluation by the Secretary. The Controlled Substances Act requires that approval of an application is delayed until the interim final rule controlling the drug is issued. The \"date of approval\" is defined as the later of the application approval date or the issuance date of the interim final rule. Conditional approval of a drug application under the Federal Food, Drug, and Cosmetic Act is delayed until the interim final rule controlling the drug is issued under the Controlled Substances Act. The Controlled Substances Act delays conditional approval of a drug application until the interim final rule controlling the drug is issued. The Controlled Substances Act delays granting approval for adding a drug to the index until the interim final rule controlling the drug is issued. The Controlled Substances Act delays approval for new animal drugs until the interim final rule controlling the drug is issued. The Controlled Substances Act requires the Attorney General to issue an interim final rule controlling newly approved drugs within 90 days of a recommendation by the Secretary of Health and Human Services. The Controlled Substances Act mandates the Attorney General to issue an interim final rule for newly approved drugs within 90 days of receiving a scheduling recommendation from the Secretary of Health and Human Services. The date for this action is determined by the later of receiving the scientific evaluation and recommendation or notification of approval for a drug application. The Attorney General is required to issue an interim final rule for newly approved drugs within 90 days of receiving a scheduling recommendation from the Secretary of Health and Human Services. The rule becomes immediately effective without needing to demonstrate good cause, allowing for public comment and hearing before a final rule is issued. Section 156 of title 35, United States Code, is amended to extend the patent term for drug products under certain conditions defined by the Secretary of Health and Human Services. The Secretary may recommend controls under the Controlled Substances Act for drug products, which upon approval or indexing, are permitted for commercial marketing or use. The term \"covered date\" refers to the later of the approval date under the Public Health Service Act. Section 303 of the Controlled Substances Act is enhanced to include provisions for new drug development, including conditional approval dates and indexing requests under the Federal Food, Drug, and Cosmetic Act. Section 303 of the Controlled Substances Act is amended to expedite registration for manufacturing controlled substances for clinical trials, with a deadline of 180 days after application acceptance. Attorney General must issue a notice of application within 90 days of acceptance, and register the applicant within 90 days after the comment period ends. Re-exportation among members of the European Economic Area is addressed in an amendment to the Controlled Substances Import and Export Act. Section 1003 of the Controlled Substances Import and Export Act is amended to allow controlled substances to be exported between European Economic Area countries, with certain conditions. Controlled substances can be exported between European Economic Area countries with specific conditions, including meeting requirements from each subsequent country and complying with certain regulations. Controlled substances exported among European Economic Area countries must meet requirements from each subsequent country and comply with specific regulations, including providing documentation within 30 days of re-exportation. The Attorney General shall not impede re-exportation of controlled substances among European Economic Area countries, including by enforcing requirements on documentation and consignee information. The Attorney General cannot enforce requirements on documentation and consignee information for re-exportation of controlled substances among European Economic Area countries. The curr_chunk is about the roles of the Speaker of the House of Representatives and the Vice President of the United States as President of the Senate."
}